Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New strategy for treating allergic disorders

01.08.2007
Oral intake of allergens or auto-antigens via the lactic acid bacterium Lactococcus lactis might be a new strategy for treating various kinds of auto-immune and allergic disorders.

VIB researchers associated with Ghent University, in collaboration with the Academic Medical Center (AMC) in Amsterdam, have shown that auto-antigens or allergens can be administered orally via the lactic acid bacterium. Based on this principle, which has been patented by VIB, ActoGeniX - a spin-off from VIB and Ghent University - is already developing a variety of biopharmaceutical medicines for a range of clinical indications.

The immune system

Every day our immune system combats harmful substances and micro-organisms that seek to penetrate our body. However, if our immune system is not working properly, we are subject to a variety of diseases. In the case of auto-immune diseases, the immune system no longer distinguishes between our body’s own substances and foreign substances and begins to attack our own tissues and organs. In other cases, the immune system responds mistakenly to harmless substances, such as the house dust mite, milk products, or pollen. This inappropriate immune system reaction to contact with such substances (allergens) is called an allergy. Today, 20% of the European population suffers from an allergy, which is twice as many sufferers compared to 15 years ago.

Lactococcus as supplier of remedies

In its natural form, the lactic acid bacterium (Lactococcus lactis) is a well-known food bacterium that has been used since time immemorial to convert milk into cheese and yoghurt. In the battle against chronic intestinal diseases, VIB researchers have been using L. lactis as a producer of a drug against gastroenteritis. The initial results of the clinical trials are promising.

Now, the bacterium is also being used to fight other disorders. There are a number of active substances for the treatment of allergies and auto-immune diseases that scientists suspect are effective in suppressing these diseases. However, it seems to be impossible to introduce these substances into the intestine in an effective manner. Pieter Rottiers and his VIB colleagues came up with the idea of calling on L. lactis once again. They introduced DNA with the code for a therapeutic protein into the bacterium’s DNA. Together with Inge L. Huibregtse, a physician at the AMC, the VIB researchers succeeded in having L. lactis produce the ovalbumin (OVA) protein.

Tested on mice

Inge L. Huibregtse (AMC) and Veerle Snoeck (VIB) evaluated the use of OVA-secreting bacteria on mice that were allergic to ovalbumin. By administering OVA-secreting bacteria, which deliver ovalbumin to the right place in the intestine, they succeeded in creating ovalbumin-tolerant mice.

Promising outlook

This research demonstrates that L. lactis can be employed to induce tolerance toward certain substances. This innovative strategy can now be developed further for the treatment of allergic and auto-immune disorders. The rising incidence of these disorders calls for more effective treatments with fewer side effects. The biopharmaceutical company ActoGeniX is playing a crucial role in the development of such new medicines. Indeed, upon its founding in 2006, ActoGeniX acquired the complete patent portfolio concerning this technology from VIB and Ghent University. ActoGeniX is now using this technology to develop a series of safe, effective medicines in a broad spectrum of disease areas.

Questions

Given that this research can raise a lot of questions, we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.

Relevant scientific publications

This research appears in the authoritative journal Gastroenterology (Huibregtse et al., Induction of OVA-specific tolerance by oral administration of Lactococcus lactis secreting OVA, Gastroenterology, 2007).
Other informative publications that preceded this research:
Braat et al., Clinical Gastroenterology and Hepatology, 4, 754-759 (2006)
Vandenbroucke et al., Gastroenterology, 127, 502-513 (2004)
Steidler et al., Nature Biotechnology, 21, 785-789 (2003)
Funding
This research has been funded by UGent and VIB.

Ann Van Gysel | alfa
Further information:
http://www.vib.be

Further reports about: ActoGeniX Gastroenterology auto-immune disorders immune system lactis

More articles from Life Sciences:

nachricht Transport of molecular motors into cilia
28.03.2017 | Aarhus University

nachricht Asian dust providing key nutrients for California's giant sequoias
28.03.2017 | University of California - Riverside

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Transport of molecular motors into cilia

28.03.2017 | Life Sciences

A novel hybrid UAV that may change the way people operate drones

28.03.2017 | Information Technology

NASA spacecraft investigate clues in radiation belts

28.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>